Sheridan, Cormac <br/><br/>
Tysabri risk causing headache for companies.  [electronic resource] 

 -  Nature reviews. Drug discovery  Sep 2005 
 - 703-4 p.  digital 
<br/><br/> Publication Type: News 
<br/><br/><label>ISSN: </label>1474-1776 
<br/><br/><label>Standard No.: </label>10.1038/nrd1837  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adverse Drug Reaction Reporting Systems--ethics<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Autoimmune Diseases--chemically induced<br/>Drug Industry--ethics<br/>Graft Rejection--prevention & control<br/>Humans<br/>Leukoencephalopathy, Progressive Multifocal--chemically induced<br/>Multiple Sclerosis--complications<br/>Natalizumab<br/>Risk Assessment--ethics<br/>United States<br/>United States Food and Drug Administration--legislation & jurisprudence